Tyrosine Veterinary Grade API (L-tyrosine, CAS 60-18-4, C₉H₁₁NO₃, relative molecular mass 181.19 g/mol) is produced under current good manufacturing practice for active pharmaceutical ingredients and is specified for veterinary tablets, injections, capsules, powders, granules, premixes, and solutions. The product designation TYR-VET-API-01 is released in three controlled subgrades: TYR-VET-API-01-P for standard powder, granulation, capsule, and tablet processes; TYR-VET-API-01-M for micronized dry blends and oral suspensions requiring finer particle control; and TYR-VET-API-01-LE for low-endotoxin solutions and injectable preparations. The powder is a white to almost white crystalline solid and is released against the current USP–NF and Ph. Eur. monographs for L-tyrosine, with a dried-basis assay window of 98.5%–101.5%. Identity is confirmed by infrared absorption spectrophotometry and specific optical rotation; the rotation is measured at 20°C on a dried sample using a 5% solution in 1 M HCl and the sodium D-line at 589 nm, with an acceptance window of -9.8° to -11.2°. This chiral identity check distinguishes the veterinary API from racemic or feed-grade amino acid powders that are not controlled for optical rotation. Loss on drying is limited to ≤0.30% after drying at 105°C for 3 h, and residue on ignition is limited to ≤0.40%. Chloride, sulfate, and iron are controlled by limit tests; certificates of analysis report residual solvents according to USP <467> and VICH GL18, elemental impurities according to USP <232>/<233> and Ph. Eur. 2.4.20, and microbial enumeration according to USP <61>/<62> for nonsterile uses. The low-endotoxin subgrade includes bacterial endotoxin release according to USP <85>; the limit is dosage-form-dependent and is commonly set at ≤0.25 EU/mg or ≤0.50 EU/mg, but the final specification must be derived from the route of administration and dose.

The pharmacopoeial limits above are release criteria for the API; the finished veterinary dosage form must separately comply with its marketing authorization specification. Residual solvent and elemental impurity data are route- and monograph-specific, not uniform across every global pharmacopoeia; when a compendial method is not available, a validated in-house method is used.

When Solid Oral Dosage Forms Require Engineered Powder Flow and Compaction Control

The standard grade TYR-VET-API-01-P is not inherently free-flowing and is not recommended as a direct-compression API without a wet-granulation or dry-granulation step. Powder flow is evaluated by USP <1174>; bulk density and tapped density are determined by USP <616> and Ph. Eur. 2.9.34. Cohesive behavior in unmodified crystalline powder increases the angle of repose above 40° in laboratory testing and requires forced-feed hoppers, vibratory feeders, or paddle agitation on high-speed capsule fillers. The compressibility index and Hausner ratio derived from bulk and tapped densities should be recorded for each incoming lot because crystal habit and particle-size distribution vary with crystallization and drying history. Direct compression of pure L-tyrosine is limited by high elastic recovery and low aqueous solubility; tablets compressed at high main-compaction force may exhibit capping or lamination. A rotary tablet press with pre-compression rollers and extended dwell time is preferred over single-station presses when direct compression is attempted, and force-displacement profiles should be used to set the main-compaction force rather than tablet hardness alone.

In production-scale wet granulation, water alone is not an optimal granulating fluid because the API remains largely undissolved at neutral pH. The neutral aqueous solubility of L-tyrosine is approximately 0.45 mg/mL at 25°C. A pH-adjusted granulating fluid or a hydroalcoholic binder is used to improve wetting and reduce binder migration. High-shear granulation endpoint should not be based solely on impeller torque; binder addition rate, chopper current, and visual mass consistency are correlated with final granule friability. Drying must be controlled because the phenolic moiety can discolor under overly aggressive hot-air conditions. Granule flow after drying is measured by USP <1174>; oversized granules are milled through a low-energy screen mill to avoid the formation of hot spots.

For tablets, blend uniformity is assessed by USP <905>, tablet friability by USP <1216>, and disintegration by USP <701>. The formulation should include a filler with plastic deformation characteristics rather than a brittle filler alone; microcrystalline cellulose and pregelatinized starch are common carriers, while dibasic calcium phosphate dihydrate may increase capping risk. Magnesium stearate should be kept at the minimum effective concentration, typically 0.25%–1.0% w/w, because shear-induced lamellar coating reduces interparticle bonding. For capsules, the standard powder is blended with 0.5%–1.5% w/w colloidal silicon dioxide and filled by tamping-pin or dosator machines; fill weight uniformity is sensitive to powder bed bulk density and requires in-process compression checks. These percentages are formulation-specific guidance, not API acceptance criteria.

Injection-Grade Solubility and Terminal Sterilization Limits

TYR-VET-API-01-LE is supplied for aqueous injectable compounding after pH adjustment. Neutral water is not a sufficient solvent for L-tyrosine; the isoelectric point is approximately 5.66, and maximum solubility in water is approximately 0.45 mg/mL at 25°C. Acidic vehicles prepared with hydrochloric acid below pH 2.0 or alkaline vehicles prepared with sodium hydroxide above pH 9.0 are used to achieve dissolved concentrations required for parenteral products. The phenolic group is susceptible to oxidation in alkaline solution, particularly in the presence of dissolved oxygen; nitrogen sparging, vacuum degassing, or an antioxidant system may be required. Terminal steam sterilization at 121°C for 15 min is not an unconditional default for tyrosine-containing injectables; pH drift, visible color change, and assay loss must be evaluated in the final container-closure system under validated sterilization conditions. Published data for this specific veterinary configuration is limited; manufacturers should conduct forced-degradation studies under ICH/VICH stability conditions before scale-up.

Sterilizing filtration through a 0.22 µm membrane is performed after complete dissolution; prefiltration with depth filters may be necessary if pH adjustment produces fine particulates. Filter compatibility must include bacterial retention, extractables, and adsorption of tyrosine onto the membrane. Final injectable solution is tested by USP <71> for sterility, USP <85> for bacterial endotoxins, and USP <788> for subvisible particulate matter. Clarity is checked by visual inspection according to the marketing authorization. The API subgrade does not replace finished-product sterility assurance; it reduces incoming endotoxin and bioburden loads to controlled limits.

For oral solutions and drench products, the same solubility constraints apply but with less stringent endotoxin control. Concentrated stock solutions are prepared in acid or base reserve; buffering salts can shift the pH toward the isoelectric point and cause recrystallization during storage. Preservative compatibility must be confirmed because charged preservatives may interact with the zwitterionic tyrosine.

Why Feed-Grade Tyrosine Cannot Substitute for a Pharmacopoeial Veterinary API

Feed-grade L-tyrosine is commonly sold on a crude protein or nitrogen-adjusted basis and is not released against a specific optical rotation, chromatographic purity, residual solvent, elemental impurity, or endotoxin specification. Without the -9.8° to -11.2° specific rotation window of TYR-VET-API-01, the L-configuration is not assured; the presence of D-tyrosine or other amino acid impurities is not excluded by a simple nitrogen assay. The veterinary API subgrades are controlled by the current USP–NF and Ph. Eur. monographs, and the certificate of analysis documents assay, related substances, chloride, sulfate, iron, loss on drying, residue on ignition, and, for the injectable grade, bacterial endotoxins. These release data are not available from feed-grade amino acid suppliers.

Residual solvent control is another boundary. Feed-grade material may retain extraction or fermentation solvents; veterinary API is tested by USP <467> and VICH GL18. Elemental impurities are controlled by USP <232>/<233> and Ph. Eur. 2.4.20. Feed-grade material may also contain higher microbial counts and may not be milled under conditions that protect the crystalline form. For low-dose tablets or premixes, the micronized grade TYR-VET-API-01-M is jet-milled and controlled by laser diffraction according to USP <429> and Ph. Eur. 2.9.31; feed-grade powder is typically a coarse, unclassified product that creates blend uniformity risk.

Oxidative Browning Is Accelerated by Moisture and Trace Metals in Multi-Ion Premixes

Premixes containing TYR-VET-API-01-P should be evaluated for moisture ingress and metal-catalyzed oxidation. Trace metals including iron and copper, commonly present as sulfate salts in mineral premixes, can accelerate oxidative discoloration of the phenolic side chain when the water activity of the premix increases. Packaging with aluminum-foil-lined bags and desiccant is recommended when storage relative humidity exceeds 60% or when ambient temperature exceeds 30°C. Reducing sugars in molasses-based carriers or dextrose-containing oral powders can undergo Maillard-type browning with the amino group; such combinations should be segregated or assessed in accelerated stability studies before commercial distribution.

For oral granules and premixes, loss on drying is controlled by USP <731>, and microbial quality by USP <61>/<62> and Ph. Eur. 2.6.12/2.6.13. The dry blend should be protected from strong oxidizing agents and from strongly alkaline carriers that promote degradation of the phenol group. In multi-component premixes, content uniformity of the amino acid is verified by a validated chromatographic method, not by total nitrogen, because total nitrogen cannot distinguish tyrosine from other nitrogenous additives.